Predictive Oncology Inc. (POAI) Balance Sheet

The consistent decline in total assets over the last ten quarters suggests that the company is consuming its capital base to fund ongoing operating losses rather than investing in growth. This trajectory implies that the business model is currently unable to generate the internal resources necessary to maintain its laboratory infrastructure.

The collapse of the current ratio from 4.24 in 2023Q2 to near-zero levels highlights a precarious liquidity position that leaves the company with virtually no buffer against operational shocks. Investors should monitor this closely, as the current cash balance appears insufficient to support even minimal ongoing research and administrative costs.

The transition to negative equity suggests that the company has effectively exhausted its book value through persistent operating deficits. This condition often complicates future financing efforts, as the balance sheet no longer provides a meaningful cushion for creditors or equity holders.